Related Experiment Videos
Interaction between fibrates and statins--metabolic interactions with gemfibrozil
Hideki Fujino1, Iwao Yamada, Shimada Shimada
1Tokyo New Drug Research Laboratories I, Kowa Company Ltd., Higashimurayama, Tokyo, Japan. h-fujino@kowa.co.jp
Drug Metabolism and Drug Interactions
|December 20, 2003
Summary
Gemfibrozil inhibits statin metabolism, increasing statin plasma concentrations. This interaction is partly due to cytochrome P450 (CYP) enzyme inhibition, particularly CYP2C8, CYP2C9, and CYP3A4.
Area of Science:
- Pharmacology
- Drug Metabolism
- Drug Interactions
Background:
- Fibrates and statins are commonly prescribed lipid-lowering medications.
- Potential drug-drug interactions between fibrates and statins require thorough investigation.
- Understanding the metabolic basis of these interactions is crucial for patient safety.
Purpose of the Study:
- To investigate the in vitro metabolic interactions between fibrates and statins.
- To elucidate the role of cytochrome P450 (CYP) enzymes in gemfibrozil-statin interactions.
Main Methods:
- In vitro study design.
- Analysis of statin metabolism in the presence of gemfibrozil.
- Dixon plot analysis to identify specific CYP enzyme inhibition.
Main Results:
- Gemfibrozil significantly inhibited the metabolism of several statins.
- Pitavastatin showed a smaller increase in its unchanged form compared to other statins.
- Dixon plots indicated gemfibrozil's inhibition of CYP2C8, CYP2C9, and CYP3A4 mediated metabolism.
Conclusions:
- Gemfibrozil-statin co-administration can lead to increased plasma concentrations of statins.
- This increase is, at least partially, attributable to CYP-mediated inhibition by gemfibrozil.
- The findings highlight the importance of considering CYP enzyme activity in managing combined fibrate-statin therapy.